Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
201-220 of 2,251 trials

Early-Stage Breast Cancer: Long-Term Follow-Up Study

We are examining the long-term health of early-stage breast cancer patients from previous studies. This research will help us understand relapse rates and overall survival.

Early Stage Invasive Breast Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: INCB099280 Study

We are testing a new medication for patients with advanced solid tumors who have not yet received immune checkpoint inhibitors. The goal is to evaluate its safety and how well it may control the disease.

Advanced Non-Small Cell Lung CancerAdvanced MelanomaUrothelial Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Head and Neck Cancer: New Imaging Technique

We are testing a new near-infrared imaging method to help surgeons detect remaining cancer cells during surgery. This study aims to improve the accuracy of tumor removal and preserve healthy tissue.

Head and Neck Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

Rituximab for Amyotrophic Lateral Sclerosis (ALS)

We are studying whether adding Rituximab to standard treatment can slow symptom progression in ALS patients. The trial also monitors safety and various health indicators.

Sporadic Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Laryngeal Cancer: ELOS Study on New Treatment

We are studying whether adding pembrolizumab to standard chemotherapy and radiation helps patients with advanced laryngeal cancer avoid laryngectomy. This trial also examines the impact on swallowing quality and overall survival.

Advanced Laryngeal and Hypopharyngeal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Stage III Lung Cancer: MK-7684A Treatment Study

We are studying a new treatment combining MK-7684A with radiation and chemotherapy for patients with unresectable Stage III lung cancer. This trial compares it to standard treatment followed by Durvalumab.

Non-small cell lung cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Cancer Study: LY3537982 for KRAS G12C Mutant Tumors

We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.

KRAS G12C-Mutant Advanced Solid TumorsSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Cancer: AZD8205 Treatment Study

We are studying the safety and early effectiveness of AZD8205, both alone and with other cancer treatments, for people with advanced or metastatic solid tumors. This research aims to find the best dose and understand how the drug works in the body.

Breast CancerOvarian CancerEndometrial CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Follicular Lymphoma: Radiotherapy with Obinutuzumab

We are studying whether adding Obinutuzumab to local radiotherapy improves outcomes for patients with early-stage Follicular Lymphoma. This trial will help us understand the effectiveness and safety of this combination treatment.

Early Stage Follicular Lymphoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Herpes Zoster Vaccine for Immunocompromised Kids

We are studying a new vaccine for children aged 1 to 17 who have had kidney transplants. The trial will help us understand its safety and how well it triggers an immune response.

Prevention of Shingles in Immunocompromised Children1-2 yearsEfficacy phase (II)No PlaceboCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePediatrics

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Primary Central Nervous System Lymphoma: MTR² Treatment Study

We are studying a new combination of medications for patients with primary central nervous system lymphoma who cannot receive intensive therapies. The goal is to see if this treatment is effective and safe, and how it affects quality of life.

Primary Central Nervous Lymphoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyNeurology

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatology

HIV-1 Treatment: Long-Acting Cabotegravir and Rilpivirine for Older Adults

We are studying a new long-acting treatment for people aged 60 and older living with HIV-1. The goal is to see if it effectively controls the virus and how it affects overall health.

HIV-1>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Kidney Stones: Furosemide Injection Study

We are investigating whether a Furosemide injection after kidney stone removal improves the chances of being stone-free and reduces the risk of infections. This study involves patients undergoing flexible ureteroscopy for kidney stones.

Kidney Stones>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementUrology